Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 4
2012 37
2013 8
2014 7
2015 6
2016 8
2017 12
2018 7
2019 5
2020 8
2021 11
2022 19
2023 13
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 33830716

102 results

Results by year

Filters applied: . Clear all
Page 1
Selumetinib.
[No authors listed] [No authors listed] 2021 Jan 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Jan 21. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 33830716 Free Books & Documents. Review.
Selumetinib: First Approval.
Markham A, Keam SJ. Markham A, et al. Drugs. 2020 Jun;80(9):931-937. doi: 10.1007/s40265-020-01331-x. Drugs. 2020. PMID: 32504375 Review.
Belumosudil.
[No authors listed] [No authors listed] 2024 Jul 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2024 Jul 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 39110823 Free Books & Documents. Review.
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Dombi E, et al. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. N Engl J Med. 2016. PMID: 28029918 Free PMC article. Clinical Trial.
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S, Zhou L, Cohen-Rabbie S, Jain L, Freshwater T, So K, He Z, Gioni I, Tomkinson H, Vishwanathan K, Zhou D. Schalkwijk S, et al. Cancer Chemother Pharmacol. 2021 Aug;88(2):189-202. doi: 10.1007/s00280-021-04274-6. Epub 2021 Apr 26. Cancer Chemother Pharmacol. 2021. PMID: 33903938
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib.
Campagne O, Yeo KK, Fangusaro J, Stewart CF. Campagne O, et al. Clin Pharmacokinet. 2021 Mar;60(3):283-303. doi: 10.1007/s40262-020-00967-y. Epub 2020 Dec 23. Clin Pharmacokinet. 2021. PMID: 33354735 Free PMC article. Review.
102 results